Key Points
- Insider Tuyl Christopher Van sold 10,813 shares on Dec. 18 at an average price of $26.91 for proceeds of $290,977.83, trimming his stake by 6.73% to 149,930 shares (≈$4.03M).
- IMVT stock traded around $26.68 (50-day MA $22.68, 200-day MA $18.42) with a market cap of $4.68B and a 12‑month range of $12.72–$27.69.
- The company reported EPS of ($0.73), missing estimates by $0.01, and analysts hold a consensus of Moderate Buy with an average target of $27.63 amid mixed ratings (1 Strong Buy, 5 Buy, 4 Hold, 1 Sell).
Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) insider Tuyl Christopher Van sold 10,813 shares of the company's stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $26.91, for a total value of $290,977.83. Following the completion of the sale, the insider owned 149,930 shares of the company's stock, valued at approximately $4,034,616.30. The trade was a 6.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Immunovant Stock Up 1.9%
IMVT stock opened at $26.68 on Friday. The business's 50-day moving average price is $22.68 and its 200-day moving average price is $18.42. The stock has a market cap of $4.68 billion, a P/E ratio of -9.39 and a beta of 0.56. Immunovant, Inc. has a twelve month low of $12.72 and a twelve month high of $27.69.
Immunovant (NASDAQ:IMVT - Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.01). During the same period in the prior year, the company posted ($0.74) EPS. On average, equities research analysts expect that Immunovant, Inc. will post -2.69 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on IMVT shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunovant in a research report on Tuesday, October 14th. Truist Financial began coverage on shares of Immunovant in a report on Tuesday, October 14th. They set a "hold" rating and a $16.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Immunovant from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 30th. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Immunovant in a research report on Thursday, September 4th. Finally, The Goldman Sachs Group boosted their price target on shares of Immunovant from $18.00 to $28.00 and gave the stock a "neutral" rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $27.63.
Read Our Latest Analysis on IMVT
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio purchased a new stake in shares of Immunovant in the first quarter valued at $27,000. Aster Capital Management DIFC Ltd bought a new position in shares of Immunovant during the third quarter valued at approximately $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Immunovant during the first quarter valued at approximately $37,000. Farther Finance Advisors LLC boosted its holdings in shares of Immunovant by 142,750.0% in the second quarter. Farther Finance Advisors LLC now owns 2,857 shares of the company's stock valued at $46,000 after purchasing an additional 2,855 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Immunovant by 138.9% in the third quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company's stock valued at $46,000 after purchasing an additional 1,646 shares during the period. 47.08% of the stock is owned by hedge funds and other institutional investors.
About Immunovant
(
Get Free Report)
Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant's approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.
The company's lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
